SHSE:688166'
s Pretax Margin % Range Over the Past 10 Years
Min: 1.14 Med: 17.72 Max: 24.46
Current: 1.72
SHSE:688166's Pretax Margin % is ranked better than 73.06% of 939
companies
in the Biotechnology industry
Industry Median: -89.42
vs SHSE:688166: 1.72
Brightgene Bio-medical Technology Co (SHSE:688166) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Brightgene Bio-medical Technology Co Pretax Margin % Related Terms
Brightgene Bio-medical Technology Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co Pretax Margin % Chart
SHSE:688166 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Brightgene Bio-medical Technology Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brightgene Bio-medical Technology Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brightgene Bio-medical Technology Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Brightgene Bio-medical Technology Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a Pretax Margin % of -1.07% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Brightgene Bio-medical Technology Co and its competitors. Over the past decade, Brightgene Bio-medical Technology Co's Pretax Margin % has ranged from 1.14 to 24.46. According to the industry distribution chart, Brightgene Bio-medical Technology Co ranks #253 out of 939 companies in the Biotechnology industry, placing it in the top 26.9%.
Is Brightgene Bio-medical Technology Co's Pretax Margin % too high?
Brightgene Bio-medical Technology Co's current Pretax Margin % is -1.07%. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 24.46. Based on the distribution chart, Brightgene Bio-medical Technology Co ranks #253 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brightgene Bio-medical Technology Co ranks #253 out of 939 companies for Pretax Margin %. This puts Brightgene Bio-medical Technology Co in the upper half of its industry. Historically, Brightgene Bio-medical Technology Co's own Pretax Margin % has ranged from 1.14 to 24.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current Pretax Margin % is -1.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current Pretax Margin % is -1.07%. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Pretax Margin % is -1.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
Pretax Margin %: -1.07%
GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
